IP Library Granted Patent US 8,124,352
Granted Patent B2
US 8,124,352 · App. 12/306,208 · Granted Feb 28, 2012

Methods and compositions for targeting HEPSIN

Assignee: Genentech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,352
App. No.
12/306,208
Granted
Feb 28, 2012
Kind
B2
Abstract

Anti-HEPSIN monoclonal antibodies, and methods for using the antibodies, are provided.

Claims (16)

1. An isolated antibody comprising (a) the heavy chain hypervariable region (HC-HVR) 1, HC-HVR2, and HC-HVR3 sequences, and (b) the light chain hypervariable region (LC-HVR) 1, LC-HVR2 and LC-HVR3 sequences of an antibody produced by hybridoma cell line deposited at American Type Culture Collection (ATCC) under Accession No. PTA-7469, PTA-7470, PTA-7471, PTA-7472 or PTA-7473, wherein said isolated antibody binds native human sequence HEPSIN polypeptide.

2. An isolated antibody comprising (a) the heavy chain variable domain sequence and/or (b) the light chain variable domain sequence of an antibody produced by hybridoma cell line deposited at American Type Culture Collection (ATCC) under Accession No. PTA-7469, PTA-7470, PTA-7471, PTA-7472 or PTA-7473, wherein said isolated antibody binds native human sequence HEPSIN polypeptide.

3. The antibody of claim 1 , wherein the full length IgG form of the antibody specifically binds native human sequence HEPSIN polypeptide with a EC 50 binding affinity of 150 nM or less.

4. The antibody of claim 3 wherein the EC 50 binding affinity is 120 nM or less.

5. The antibody of claim 3 wherein the EC 50 binding affinity is 100 nM or less.

6. The antibody of claim 3 wherein the EC 50 binding affinity is 75 nM or less.

7. The antibody of claim 3 wherein the EC 50 binding affinity is 50 nM or less.

8. The antibody of claim 1 , wherein the antibody specifically binds native sequence HEPSIN polypeptide that is in native, partially denatured or denatured form.

9. The antibody of claim 1 , wherein the antibody binds soluble or cell-attached native sequence HEPSIN polypeptide.

10. An anti-HEPSIN antibody encoded by the antibody coding sequence of hybridoma cell line deposited at the American Type Culture Collection (ATCC) under Accession No. PTA-7469, PTA-7470, PTA-7471, PTA-7472 or PTA-7473.

11. A nucleic acid molecule comprising a nucleic acid sequence encoding the antibody of claim 1 .

12. A host cell comprising the nucleic acid molecule of claim 11 .

13. A cell line capable of producing the antibody of claim 1 .

14. A method of producing the antibody of claim 1 , comprising culturing a host cell comprising a nucleic acid encoding the antibody under conditions wherein the antibody is produced.

15. A composition comprising the antibody of claim 1 , and a carrier.

16. A method of detecting presence of native sequence HEPSIN polypeptide in a sample, comprising contacting the sample with an antibody of claim 1 and diagnosing presence of native sequence HEPSIN polypeptide by detecting binding of the antibody to HEPSIN polypeptide, wherein detection of binding indicates the presence of native sequence HEPSIN polypeptide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2012
From: KIRCHHOFER, DANIEL K.; VIJ, RAJESH
To: GENENTECH, INC.
Reel/Frame 027479/0348 →
Continuity (2)
Provisional Application 60805589 · Jun 22, 2006
Related Publication 20100021474A1 · Jan 28, 2010